Introducing a New Article Series: How I Treat Side Effects of Immunotherapy

Overview

Journal ESMO Open

Publisher Elsevier

Specialty Oncology

Date 2019 Jul 30

PMID 31354967

Citations 1

Authors

Matthias Preusser

Affiliations

Soon will be listed here.

Citing Articles

Announcing the special issue on upcoming molecular targets for cancer treatment.

Morgan G, Preusser M, Zielinski C ESMO Open. 2020; 5(Suppl 2).

PMID: 32312740 PMC: 7204807. DOI: 10.1136/esmoopen-2020-000734.

References

Popovic L, Matovina-Brko G, Popovic M . Checkpoint inhibitors in the treatment of urological malignancies. ESMO Open. 2017; 2(2):e000165. PMC: 5519795. DOI: 10.1136/esmoopen-2017-000165. View

Rodriguez-Vida A, Hutson T, Bellmunt J, Strijbos M . New treatment options for metastatic renal cell carcinoma. ESMO Open. 2017; 2(2):e000185. PMC: 5519813. DOI: 10.1136/esmoopen-2017-000185. View

Granier C, de Guillebon E, Blanc C, Roussel H, Badoual C, Colin E . Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer. ESMO Open. 2017; 2(2):e000213. PMC: 5518304. DOI: 10.1136/esmoopen-2017-000213. View

Economopoulou P, Kotsantis I, Psyrri A . The promise of immunotherapy in head and neck squamous cell carcinoma: combinatorial immunotherapy approaches. ESMO Open. 2017; 1(6):e000122. PMC: 5548974. DOI: 10.1136/esmoopen-2016-000122. View

Nishio M, Hida T, Atagi S, Sakai H, Nakagawa K, Takahashi T . Multicentre phase II study of nivolumab in Japanese patients with advanced or recurrent non-squamous non-small cell lung cancer. ESMO Open. 2017; 1(4):e000108. PMC: 5566979. DOI: 10.1136/esmoopen-2016-000108. View

Saraiva D, Cabral M, Jacinto A, Braga S . How many diseases is triple negative breast cancer: the protagonism of the immune microenvironment. ESMO Open. 2017; 2(4):e000208. PMC: 5604720. DOI: 10.1136/esmoopen-2017-000208. View

Kastrisiou M, Kostadima F, Kefas A, Zarkavelis G, Kapodistrias N, Ntouvelis E . Nivolumab-induced hypothyroidism and selective pituitary insufficiency in a patient with lung adenocarcinoma: a case report and review of the literature. ESMO Open. 2017; 2(4):e000217. PMC: 5640091. DOI: 10.1136/esmoopen-2017-000217. View

Doherty G, Duckworth A, Davies S, Mells G, Brais R, Harden S . Severe steroid-resistant anti-PD1 T-cell checkpoint inhibitor-induced hepatotoxicity driven by biliary injury. ESMO Open. 2017; 2(4):e000268. PMC: 5652580. DOI: 10.1136/esmoopen-2017-000268. View

Grob J, Mortier L, DHondt L, Grange F, Baurain J, Dreno B . Safety and immunogenicity of MAGE-A3 cancer immunotherapeutic with dacarbazine in patients with MAGE-A3-positive metastatic cutaneous melanoma: an open phase I/II study with a first assessment of a predictive gene signature. ESMO Open. 2017; 2(5):e000203. PMC: 5687540. DOI: 10.1136/esmoopen-2017-000203. View

10.

Solinas C, Gombos A, Latifyan S, Piccart-Gebhart M, Kok M, Buisseret L . Targeting immune checkpoints in breast cancer: an update of early results. ESMO Open. 2017; 2(5):e000255. PMC: 5687552. DOI: 10.1136/esmoopen-2017-000255. View

11.

Ramos-Esquivel A, van der Laat A, Rojas-Vigott R, Juarez M, Corrales-Rodriguez L . Anti-PD-1/anti-PD-L1 immunotherapy versus docetaxel for previously treated advanced non-small cell lung cancer: a systematic review and meta-analysis of randomised clinical trials. ESMO Open. 2017; 2(3):e000236. PMC: 5699523. DOI: 10.1136/esmoopen-2017-000236. View

12.

Cheung M, Chan K, Sabharwal M, Fields A, Chambers A, Evans W . Comparing assessment frameworks for cancer drugs between Canada and Europe: What can we learn from the differences?. ESMO Open. 2017; 1(6):e000124. PMC: 5703384. DOI: 10.1136/esmoopen-2016-000124. View

13.

Aguiar Jr P, de Mello R, Barreto C, Perry L, Penny-Dimri J, Tadokoro H . Immune checkpoint inhibitors for advanced non-small cell lung cancer: emerging sequencing for new treatment targets. ESMO Open. 2017; 2(3):e000200. PMC: 5703392. DOI: 10.1136/esmoopen-2017-000200. View

14.

Norum J, Antonsen M, Tollali T, Al-Shibli K, Andersen G, Svanqvist K . Pembrolizumab as second-line therapy in non-small cell lung cancer in northern Norway: budget impact and expected gain-a model-based analysis. ESMO Open. 2017; 2(3):e000222. PMC: 5703383. DOI: 10.1136/esmoopen-2017-000222. View

15.

Cheng S, Qureshi M, Pullenayegum E, Haynes A, Chan K . Do patients with reduced or excellent performance status derive the same clinical benefit from novel systemic cancer therapies? A systematic review and meta-analysis. ESMO Open. 2017; 2(4):e000225. PMC: 5623318. DOI: 10.1136/esmoopen-2017-000225. View

16.

Leduc C, Adam J, Louvet E, Sourisseau T, Dorvault N, Bernard M . TPF induction chemotherapy increases PD-L1 expression in tumour cells and immune cells in head and neck squamous cell carcinoma. ESMO Open. 2018; 3(1):e000257. PMC: 5761289. DOI: 10.1136/esmoopen-2017-000257. View

17.

Geukes Foppen M, Rozeman E, van Wilpe S, Postma C, Snaebjornsson P, van Thienen J . Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management. ESMO Open. 2018; 3(1):e000278. PMC: 5786923. DOI: 10.1136/esmoopen-2017-000278. View

18.

Glitza I, Rohlfs M, Guha-Thakurta N, Bassett Jr R, Bernatchez C, Diab A . Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2. ESMO Open. 2018; 3(1):e000283. PMC: 5786950. DOI: 10.1136/esmoopen-2017-000283. View

19.

Cho J, Chang Y, Heo Y, Kim S, Kim N, Park J . Four distinct immune microenvironment subtypes in gastric adenocarcinoma with special reference to microsatellite instability. ESMO Open. 2018; 3(3):e000326. PMC: 5890063. DOI: 10.1136/esmoopen-2018-000326. View

20.

Pinto J, Vallejos C, Raez L, Mas L, Ruiz R, Torres-Roman J . Gender and outcomes in non-small cell lung cancer: an old prognostic variable comes back for targeted therapy and immunotherapy?. ESMO Open. 2018; 3(3):e000344. PMC: 5905840. DOI: 10.1136/esmoopen-2018-000344. View